180 related articles for article (PubMed ID: 21491078)
1. Differential expression of ETS family members in prostate cancer tissues and androgen-sensitive and insensitive prostate cancer cell lines.
Adler D; Lindstrot A; Langer B; Buettner R; Wernert N
Int J Mol Med; 2011 Jul; 28(1):89-93. PubMed ID: 21491078
[TBL] [Abstract][Full Text] [Related]
2. Ets-1 is implicated in the regulation of androgen co-regulator FHL2 and reveals specificity for migration, but not invasion, of PC3 prostate cancer cells.
Adler D; Langer B; Lindstrot A; Florin A; Bosserhoff A; Buettner R; Wernert N
Oncol Rep; 2011 Apr; 25(4):1125-9. PubMed ID: 21258770
[TBL] [Abstract][Full Text] [Related]
3. ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).
Adler D; Wernert N
Int J Oncol; 2012 Jun; 40(6):1748-54. PubMed ID: 22366814
[TBL] [Abstract][Full Text] [Related]
4. Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression.
Alder D; Braun M; Nikolov P; Boehm D; Scheble V; Menon R; Fend F; Kristiansen G; Perner S; Wernert N
Hum Pathol; 2012 Nov; 43(11):1910-6. PubMed ID: 22569213
[TBL] [Abstract][Full Text] [Related]
5. ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.
Adler D; Ochsenfahrt J; Fuchs K; Kristiansen G; Perner S; Wernert N
Int J Mol Med; 2012 Nov; 30(5):1029-33. PubMed ID: 22922762
[TBL] [Abstract][Full Text] [Related]
6. Novel identification of the ETS-1 splice variants p42 and p27 in prostate cancer cell lines.
Adler D; Ochsenfahrt J; Fuchs K; Wernert N
Oncol Rep; 2012 May; 27(5):1321-4. PubMed ID: 22307076
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive gene expression microarray analysis of Ets-1 blockade in PC3 prostate cancer cells and correlations with prostate cancer tissues: Insights into genes involved in the metastatic cascade.
Adler D; Lindstrot A; Langer B; Buettner R; Wernert N
Int J Mol Med; 2011 Jun; 27(6):811-9. PubMed ID: 21424114
[TBL] [Abstract][Full Text] [Related]
8. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
[TBL] [Abstract][Full Text] [Related]
9. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
10. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
11. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract][Full Text] [Related]
12. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?
Adler D; Lindstrot A; Ellinger J; Rogenhofer S; Buettner R; Perner S; Wernert N
Mol Med Rep; 2012 Feb; 5(2):313-6. PubMed ID: 22038307
[TBL] [Abstract][Full Text] [Related]
13. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
14. ETS gene fusions in prostate cancer.
Clark JP; Cooper CS
Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
[TBL] [Abstract][Full Text] [Related]
15. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
[TBL] [Abstract][Full Text] [Related]
16. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
17. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
[TBL] [Abstract][Full Text] [Related]
18. Five ETS family members, ELF-1, ETV-4, ETV-3L, ETS-1, and ETS-2 upregulate human leukocyte-associated immunoglobulin-like receptor-1 gene basic promoter activity.
Cao Q; Yang S; Lv Q; Liu Y; Li L; Wu X; Qu G; He X; Zhang X; Sun S; Li B; An J; Hu T; Xue J
Aging (Albany NY); 2018 Jun; 10(6):1390-1401. PubMed ID: 29915163
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
20. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
